I don't get the market reaction. What was announced today is what was announced a few months ago. FY18, even with flat dose sales, will see a reduction in employee and marketing costs that is material. That alone should cater see EPS grow. Add to that the increased net cash, and the upside of any success from trials/sales from trial results. There is a margin of safety here in my opinion.
Ann: Sirtex Records Underlying Full Year NPAT of $42.4 Million, page-31
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.008(4.92%) |
Mkt cap ! $67.91M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.5¢ | $399.7K | 2.5M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 141094 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |